NRX Pharmaceuticals, Inc.

Big Rock Partners Acquisition Corp (Nasdaq: BRPA), sponsored by Big Rock Partners, LLC, was a blank-check company that completed its business combination with NRX Pharmaceuticals, Inc. in early 2021. The SPAC had its initial public offering in 2018 and targeted the healthcare and biopharmaceutical sector. NRX Pharmaceuticals focuses on the development of treatments for critical illnesses, including respiratory and central nervous system conditions. The April 2021 8-K filing, bearing accession number 0001654954-21-004488, was submitted in the wake of the completed de-SPAC transaction as the combined company moved forward under the NRX Pharmaceuticals name. Sign up at SpacDesk for full filing history, deal timelines, and analytics on BRPA and hundreds of other SPAC transactions.